Mode
Text Size
Log in / Sign up
N/A N=43 Treatment

A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality

Prostate Cancer · Head and Neck Cancers · Upper Abdomen Cancers

Enrolled (actual)
43
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Ratio of Standard CBCT to Research CBCT HU Error in Photon Therapy Participants — 1.768 Ratio (unitless) — p=0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Research CBCT (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
May 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Ratio of Standard CBCT to Research CBCT HU Error in Photon Therapy Participants
1.768 0.0001 sig
PRIMARY
Median Shift in Hounsfield Unit (HU) Error Between Standard CBCT and Research CBCT in Proton Therapy Participants
-128.8 0.001953 sig
PRIMARY
Ratio of Artifact Amplitude Between Standard CBCT and Research CBCT in Photon Therapy Participants
1.489 0.0001 sig
PRIMARY
Median Shift in Artifact Amplitude (Measured in Hounsfield Units) Between Standard CBCT and Research CBCT in Proton Therapy Participants
-235.9 0.001953 sig
PRIMARY
Ratio of Contrast-To-Noise Ratio (CNR) Between Standard CBCT and Research CBCT in Photon Therapy Participants
1.199 0.0001 sig
PRIMARY
Median Shift in Contrast to Noise Ratio (CNR) Between Standard CBCT and Research CBCT in Proton Therapy Participants
0.56 0.001953 sig
SECONDARY
Accuracy of Automated Tissue Delineation in CBCT Images for Photon Therapy Participants. Difference in Dice Similarity Coefficient Between Research CBCT and Standard CBCT
-0.065 0.0001 sig

Summary

This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improvement in tissue visualization in an observer study, which will be conducted in a blinded fashion.

Eligibility Criteria

Inclusion Criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Be a male or female aged 18-100.
  • Participants who will be treated or are currently being treated with CBCT-guided photon therapy for prostate or prostate-bed, abdomen head and neck, or pelvic cancers, or with image-guided proton therapy for prostate or prostate bed cancer.

Exclusion Criteria

  • Metallic implants in the CBCT scan volume, such as hip prostheses or spine stabilization hardware. Patients with pacemakers, defibrillators, or other implanted electronic devices. Dental implants, fillings, or fiducial markers may be acceptable, and the decision for inclusion/exclusion will be on a case-by-case basis, by reviewing prior CT images of the study candidate. Patient's prior CT images will be reviewed by the PI or the site PI.
  • Patients who do not have the ability to lie still for the duration of his/her CBCT imaging and treatment should be excluded. If image artifacts in prior scans are deemed excessive, the patient will be excluded from the study.
  • Known pregnancy. (Per SOC, a pregnancy test will be performed prior to CBCT scan on Day 1. At this time, women of child-bearing potential (WOCBP) will receive a pregnancy test to re-confirm eligibility).
  • Women of child-bearing potential are described as:
  • Age 55 or younger who have not had a negative pregnancy test within 3 days. This excludes patients who have had tubal ligation or are already post-menopausal.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04565457). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search